The role of complement in autoimmune renal disease

References

• Walport MJ. Complement. Second of two parts. N Engl J Med 2001; 344: 1140–1144
   PubMed Web of Science ®Google Scholar
• Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344: 1058–1066
   PubMed Web of Science ®Google Scholar
• Turner N, Mason PJ, Brown R, et al. Molecular cloning of the human Goodpasture antigen demonstrates it to be the alpha 3 chain of type IV collagen. J Clin Invest 1992; 89: 592–601
   PubMed Web of Science ®Google Scholar
• Sheerin NS, Springall T, Carroll MC, Hartley B, Sacks SH. Protection against anti-glomerular basement membrane (GBM)-mediated nephritis in C3- and C4-deficient mice. Clin Exp Immunol 1997; 110: 403–409
   PubMed Web of Science ®Google Scholar
• Cunningham PN, Quigg RJ. Contrasting roles of complement activation and its regulation in membranous nephropathy. J Am Soc Nephrol 2005; 16: 1214–1222
   Google Scholar
• Appel GB, Cook HT, Hageman G, et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): An update. J Am Soc Nephrol 2005; 16: 1392–1403
   PubMed Web of Science ®Google Scholar
• Daha MR, Hazevoet HM, Vanes LA, Cats A. Stabilization of the classical pathway C3 convertase C42, by a factor F-42, isolated from serum of patients with systemic lupus erythematosus. Immunology 1980; 40: 417–424
   Google Scholar
• Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003; 56: 481–490
   PubMed Web of Science ®Google Scholar
• Walport MJ, Davies KA, Botto M. C1q and systemic lupus erythematosus. Immunobiology 1998; 199: 265–285
   PubMed Web of Science ®Google Scholar
• Siegert C, Daha M, Westedt ML, van der Voort E, Breedveld F. IgG autoantibodies against C1q are correlated with nephritis, hypocomplementemia, and dsDNA antibodies in systemic lupus erythematosus. J Rheumatol 1991; 18: 230–234
   PubMed Web of Science ®Google Scholar
• Smeenk R, Brinkman K, van den Brink H, et al. Antibodies to DNA in patients with systemic lupus erythematosus. Their role in the diagnosis, the follow-up and the pathogenesis of the disease. Clin Rheumatol 1990; 9: 100–110
   Google Scholar
• Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526–1533
   PubMed Web of Science ®Google Scholar
• Gunnarsson I, Sundelin B, Heimburger M, et al. Repeated renal biopsy in proliferative lupus nephritis–predictive role of serum C1q and albuminuria. J Rheumatol 2002; 29: 693–699
   PubMed Web of Science ®Google Scholar
• Mannik M, Wener MH. Deposition of antibodies to the collagen-like region of C1q in renal glomeruli of patients with proliferative lupus glomerulonephritis. Arthritis Rheum 1997; 40: 1504–1511
   Google Scholar
• Trouw LA, Seelen MA, Visseren R, et al. Anti-C1q autoantibodies in murine lupus nephritis. Clin Exp Immunol 2004; 135: 41–48
   PubMed Web of Science ®Google Scholar
• Winfield JB, Faiferman I, Koffler D. Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus. Association of high avidity antinative DNA antibody with glomerulonephritis. J Clin Invest 1977; 59: 90–96
   PubMed Web of Science ®Google Scholar
• Trouw LA, Seelen MA, Duijs JM, Benediktsson H, van Kooten C, Daha MR. Glomerular deposition of C1q and anti-C1q antibodies in mice following injection of antimouse C1q antibodies. Clin Exp Immunol 2003; 132: 32–39
   PubMed Web of Science ®Google Scholar
• Trouw LA, Groeneveld TW, Seelen MA, et al. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest 2004; 114: 679–688
   PubMed Web of Science ®Google Scholar
• Trouw LA, Daha MR. Role of anti-C1q autoantibodies in the pathogenesis of lupus nephritis. Expert Opin Biol Ther 2005; 5: 243–251
   PubMed Web of Science ®Google Scholar
• Manderson AP, Botto M, Walport MJ. The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 2004; 22: 431–456
   PubMed Web of Science ®Google Scholar
• Botto M, Walport MJ. C1q, autoimmunity and apoptosis. Immunobiology 2002; 205: 395–406
   PubMed Web of Science ®Google Scholar
• Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994; 179: 1317–1330
   PubMed Web of Science ®Google Scholar
• Nauta AJ, Daha MR, van Kooten C, Roos A. Recognition and clearance of apoptotic cells: A role for complement and pentraxins. Trends Immunol 2003; 24: 148–154
   PubMedGoogle Scholar
• Ogden CA, deCathelineau A, Hoffmann PR, et al. C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J Exp Med 2001; 194: 781–795
   PubMed Web of Science ®Google Scholar
• Botto M, Dell'Agnola C, Bygrave AE, et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998; 19: 56–59
   PubMed Web of Science ®Google Scholar
• Mold C, Baca R, Du Clos TW. Serum amyloid P component and C-reactive protein opsonize apoptotic cells for phagocytosis through Fcgamma receptors. J Autoimmun 2002; 19: 147–154
   PubMedGoogle Scholar
• Nauta AJ, Raaschou-Jensen N, Roos A, et al. Mannose-binding lectin engagement with late apoptotic and necrotic cells. Eur J Immunol 2003; 33: 2853–2863
   PubMedGoogle Scholar
• Shaw PX, Horkko S, Chang MK, et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 2000; 105: 1731–1740
   PubMed Web of Science ®Google Scholar
• Trouw LA, Seelen MA, Duijs JM, et al. Activation of the lectin pathway in murine lupus nephritis. Mol Immunol 2005; 42: 731–740
   Google Scholar
• Asghar SS, Pasch MC. Therapeutic inhibition of the complement system, Y2K update. Front Biosci 2000; 5: E63–E81
   PubMed Web of Science ®Google Scholar
• Bao L, Haas M, Kraus DM, et al. Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice. J Am Soc Nephrol 2003; 14: 670–679
   PubMed Web of Science ®Google Scholar
• Couser WG, Johnson RJ, Young BA, Yeh CG, Toth CA, Rudolph AR. The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis. J Am Soc Nephrol 1995; 5: 1888–1894
   Google Scholar
• Bao L, Osawe I, Puri T, Lambris JD, Haas M, Quigg RJ. C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. Eur J Immunol 2005; 35: 2496–2506
   PubMed Web of Science ®Google Scholar
• Wang Y, Hu Q, Madri JA, Rollins SA, Chodera A, Matis LA. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci U.S.A 1996; 93: 8563–8568
   PubMed Web of Science ®Google Scholar